Keywords: کارفیلزیمیب; Proteasome; Babesia; Carfilzomib; Epoxyketone; Cytotoxicity;
مقالات ISI کارفیلزیمیب (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: کارفیلزیمیب; Multiple myeloma; Bortezomib; Carfilzomib; Proteasome inhibitor;
Keywords: کارفیلزیمیب; Carfilzomib; Proteasome inhibition; Cardiotoxicity; Endothelial dysfunction;
Keywords: کارفیلزیمیب; BTZ; bortezomib; CFZ; carfilzomib; C-L; caspase-like; CNS; central nervous system; CT-L; chymotrypsin-like; CYPs; cytochrome P450 enzymes; iP; immunoproteasome; IXZ; ixazomib; MM; multiple myeloma; OPZ; oprozomib; PD; pharmacodynamic; PI; proteasome inhib
Keywords: کارفیلزیمیب; AE; Adverse event; BIPN; Bortezomib-induced peripheral neuropathy; C-L; Caspase-like; CFZ; Carfilzomib; ChT-L; Chymotrypsin-like action; IRd; Ixazomib, lenalidomide, and dexamethasone; LG; Leaving group; MM; Multiple myeloma; MTD; Maximum tolerated dose;
Keywords: کارفیلزیمیب; myeloma treatment; carfilzomib; bortezomib; toxicity;
Keywords: کارفیلزیمیب; Carfilzomib; Proteasome inhibitors; Multiple myeloma; Coronary resistance; Vascular tone;
Keywords: کارفیلزیمیب; Autologous stem cell transplantation; Carfilzomib; Daratumumab; Ixazomib; Multiple myeloma;
Keywords: کارفیلزیمیب; Carfilzomib; Daratumumab; Elotuzumab; Pomalidomide; Refractory; Treatment; Transplant;
Keywords: کارفیلزیمیب; AIF; apoptosis inducing factor; Ang; angiopoietin; AP-1; activator protein-1; APEX; Assessment of Proteasome Inhibition for Extending Remissions; ATP; adenosine-5â²-triphosphate; BiPN; bortezomib-induced peripheral neuropathy; CiPN; chemotherapy-induced
Keywords: کارفیلزیمیب; Rituximab; Ibrutinib; Bortezomib; Carfilzomib; Fludarabine;
Keywords: کارفیلزیمیب; Heparanase; Chemotherapy; Multiple myeloma; Proteasome inhibitors; NF-κB; Roneparstat; HPSE; heparanase; (NF-κB); nuclear factor-kappa B; SDC1; syndecan-1; BTZ; bortezomib; CFZ; carfilzomib; HGF; hepatocyte growth factor; VEGF; vascular endothelial grow
Keywords: کارفیلزیمیب; szpiczak plazmocytowy; niewydolność nerek; talidomid; lenalidomid; bortezomib; karfilzomibMultiple myeloma; Renal insufficiency; Thalidomide; Lenalidomide; Bortesomib; Carfilzomib
Keywords: کارفیلزیمیب; Carfilzomib; proteasome inhibitor; heart failure; chemotherapy
Keywords: کارفیلزیمیب; BCL-XL; Myc/B cell extra-large; b.i; bone implant; BM; bone marrow; BMD; bone mineral density; Bort; bortezomib; β2M; β2Microglobulin; Car; carfilzomib; CP; cyclophosphamide; Dex; dexamethasone; DKK1; Dickkopf-1; Dox; doxorubicin; GFP; green fluorescent
Keywords: کارفیلزیمیب; Proteasome; Bortezomib; Carfilzomib; Ixazomib citrate; MLN9708;
Keywords: کارفیلزیمیب; Peripheral neurophathy; Proteasome inhibitors; Neurotoxicity; Bortezomib; Carfilzomib
Keywords: کارفیلزیمیب; Carfilzomib; Proteasome inhibitor; Hepatocellular carcinoma
Keywords: کارفیلزیمیب; Multiple myeloma; Proteasome inhibitor; Therapy; Oral administration; Bortezomib; Carfilzomib; Marizomib; Ixazomib; Delanzomib;
Keywords: کارفیلزیمیب; Carfilzomib; Proteasome inhibitor; Relapsed; Refractory; Newly-diagnosed; Multiple myeloma; Dosing; Schedule;
Keywords: کارفیلزیمیب; Bortezomib; Carfilzomib; Cytogenetics; Dexamethasone; Immunotherapy; Lenalidomide; Next-generation sequencing
A functional drug re-purposing screening identifies carfilzomib as a drug preventing 17β-estradiol: ERα signaling and cell proliferation in breast cancer cells
Keywords: کارفیلزیمیب; 17β-estradiol; Estrogen receptor; Breast cancer; Drug screening; Carfilzomib;
Proteasome Inhibitors in Waldenström Macroglobulinemia
Keywords: کارفیلزیمیب; Bortezomib; Carfilzomib; Oprozomib; Ixazomib; Unfolded protein response;
Irreversible proteasome inhibition with carfilzomib as first line therapy in patients with newly diagnosed multiple myeloma: Early in vivo cardiovascular effects
Keywords: کارفیلزیمیب; Carfilzomib; Cardiovascular effects; Cancer therapy; EndoPAT;
BaxÎ2 sensitizes colorectal cancer cells to proteasome inhibitor-induced cell death
Keywords: کارفیلزیمیب; BaxÎ2; Cell death; Proteasome inhibitors; Cancer therapy; Bortezomib; Carfilzomib;
Phase 1/2 Trial of Carfilzomib Plus High-Dose Melphalan Preparative Regimen for Salvage Autologous Hematopoietic Cell Transplantation Followed by Maintenance Carfilzomib in Patients with Relapsed/Refractory Multiple Myeloma
Keywords: کارفیلزیمیب; Multiple myeloma; Melphalan; Carfilzomib; Peripheral blood stem cell transplantation; Autologous transplantation;
Progress curve analysis of the kinetics of slow-binding anticancer drug inhibitors of the 20S proteasome
Keywords: کارفیلزیمیب; Bortezomib; Proteasome; Carfilzomib; Slow-binding; Ixazomib; Inhibitor; EDTA; ethylenediaminetetraacetic acid; HEPES; 4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid; Suc-LLVY-AMC; N-succinyl-Leu-Leu-Val-Tyr-7-amino-4-methylcoumarin; λEx and λEm; exc
Curcumin ameliorates the in vitro efficacy of carfilzomib in human multiple myeloma U266 cells targeting p53 and NF-κB pathways
Keywords: کارفیلزیمیب; Myeloma; Curcumin; Carfilzomib; NF-κB; p53; Proteasome inhibitor;
A Multicenter, Open-Label, Phase 1b Study of Carfilzomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients (CHAMPION-2)
Keywords: کارفیلزیمیب; Carfilzomib; Clinical trial; Multiple myeloma; Newly diagnosed; Proteasome inhibitor;
Proteasome inhibitors to alleviate aberrant IKBKAP mRNA splicing and low IKAP/hELP1 synthesis in familial dysautonomia
Keywords: کارفیلزیمیب; Familial dysautonomia; Proteasome; Carfilzomib; IKBKAP; mRNA splicing; MicroRNA;
Carfilzomib induces G2/M cell cycle arrest in human endometrial cancer cells via upregulation of p21Waf1/Cip1 and p27Kip1
Keywords: کارفیلزیمیب; carfilzomib; cell cycle; endometrial carcinoma;
Bortezomib and ixazomib protect firefly luciferase from degradation and can flaw respective reporter gene assays
Keywords: کارفیلزیمیب; Bortezomib; Carfilzomib; Firefly luciferase; Inhibition; Ixazomib; Reporter gene assay; PXR; pregnane-X-receptor; RT-qPCR; reverse transcription-quantitative polymerase chain reaction; DMSO; dimethyl sulfoxide; PBS; phosphate-buffered saline; BSA; bov
Nephrotoxicity of epigenetic inhibitors used for the treatment of cancer
Keywords: کارفیلزیمیب; Epigenetic inhibitors; Prostate cancer; Kidney cells; Nephrotoxicity; 5-Aza; 5-aza-2ʹ-deoxycytidine; CBZ; carbamazapine; CDK; cyclin-dependent kinase; CDKN1a; cyclin-dependent kinase inhibitor 1a; CFZ; carfilzomib; ChIP; chromatin immunoprecipitation; DM
A UHPLC-UV-QTOF study on the stability of carfilzomib, a novel proteasome inhibitor
Keywords: کارفیلزیمیب; Carfilzomib; Degradation kinetics; Proteasome inhibitor; Stability indicating method; Stress test; UHPLC-UV- QTOF
Inhibition of autophagy with chloroquine potentiates carfilzomib-induced apoptosis in myeloma cells in vitro and in vivo
Keywords: کارفیلزیمیب; Carfilzomib; Apoptosis; Autophagy; Immunogenic cell death; Myeloma
Carfilzomib promotes the osteogenic differentiation potential of mesenchymal stem cells derived from myeloma patients by inhibiting notch1 activity in vitro
Keywords: کارفیلزیمیب; Mesenchymal stem cells; Notch1; Osteogenic differentiation; Multiple myeloma; Carfilzomib
Liposomal carfilzomib nanoparticles effectively target multiple myeloma cells and demonstrate enhanced efficacy in vivo
Keywords: کارفیلزیمیب; Carfilzomib; Nanoparticle; Liposome; Multiple myeloma; Proteasome inhibitor;
The role of the ubiquitin proteasome system in lymphoma
Keywords: کارفیلزیمیب; Ubiquitin proteasome system; Lymphoma; Bortezomib; Carfilzomib; Marizomib; CEP-18770; Clinical trials-UPS inhibitors;
An Open-Label Single-Arm Pilot Phase II Study (PX-171-003-A0) of Low-Dose, Single-Agent Carfilzomib in Patients With Relapsed and Refractory Multiple Myeloma
Keywords: کارفیلزیمیب; Carfilzomib; Next generation; Proteasome inhibitor; Targeted therapy
Proteasome inhibitors in mantle cell lymphoma
Keywords: کارفیلزیمیب; non-Hodgkin's lymphoma; proteasome inhibitor; mantle cell lymphoma; bortezomib; carfilzomib